A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Exclusion Criteria

• •1. In previous treatment, he received highly selective colony stimulating factor 1 receptor (CSF-1R) targeted therapy, including small molecule or large molecule drugs;
• •2. A known history of allergy to components of the investigational drug composition ;
• •3. Patients continued to use CYP3A4 in combination with antifungal agents or in the two weeks prior to the initial administration of ABSK021 Strong inducer;
• •4. The patient has received more than 5 lines of systemic therapy for cGvHD;
• •5. The patient presented with aGvHD symptoms without cGvHD symptoms ;
• •6. Any evidence of potential tumor or recurrence of post-transplant lymphoproliferative disease at the screening stage .
• •7. There are factors that have been determined by the investigators to have a significant influence on oral drug absorption
• •8. Present with cholestatic disease, or unresolved hepatic sinus obstruction syndrome/venous obstructive disease;
• •9. active infection.
• •10. During the screening period, the investigators judged that the patients had insufficient pulmonary function reserve, with FEV1≤ 39% or pulmonary function classification score of 3;
• •11. Prior treatment (adverse events did not return to ≤ Grade 2 (CTCAE v5.0);
• •12. Pregnant or lactating women;
• •13. Patients who are unable to or disagree with contraception.